Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany

Kulp W, Hemels M, Greiner W, von der Schulenburg J (2005) Value in Health, 8(6). Blackwell: A210.

Download
No fulltext has been uploaded. References only!
Conference Abstract | Published | English

No fulltext has been uploaded

Author
; ; ;
Publishing Year
ISSN
PUB-ID

Cite this

Kulp W, Hemels M, Greiner W, von der Schulenburg J. Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany.
Kulp, W., Hemels, M., Greiner, W., & von der Schulenburg, J. (2005). Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. Presented at the .
Kulp, W., Hemels, M., Greiner, W., and von der Schulenburg, J. (2005).“Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany”.
Kulp, W., et al., 2005. Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany.
W. Kulp, et al., “Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany”, Blackwell, 2005.
Kulp, W., Hemels, M., Greiner, W., von der Schulenburg, J.: Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. (2005).
Kulp, W., Hemels, M., Greiner, Wolfgang, and von der Schulenburg, J. “Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany”., Blackwell, 2005.
This data publication is cited in the following publications:
This publication cites the following data publications:

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Search this title in

Google Scholar